IMPORTANT UPDATE
The Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) has gone into effect, as of 4/24/25, ending reimbursement for PancraGEN®.

Because PancraGEN is primarily ordered for Medicare patients, this means that Interpace Diagnostics can no longer offer PancraGEN and the related Point2® fluid chemistry tests for amylase, CEA, glucose.

Specimens and orders for PancraGEN and fluid chemistry testing received after May 2, 2025* will not be accepted for testing.

Please plan accordingly.

*The last shipping date using FedEx Priority Overnight would be Thursday, May 1st. (Ensure the FedEx pickup time cutoff is met)

ThyGeNEXT®+ThyraMIR®v2 testing for indeterminate thyroid nodules continues to remain available without interruption.

View Details



User Name:
(email address)  
Password:
Register New Account Forgot Password?
Request Account Changes